Our Pricing

Buy Prescription Appetite Suppressant Shot Online UK

Published on: June 03, 2026

Looking to buy prescription appetite suppressant shot online UK with expert clinical support? Cured Pharmacy offers genuine GLP-1 receptor agonist injections from £135.00 dispensed by our UK-registered clinical team following a free online consultation that takes under three minutes.

How Prescription Appetite Suppressant Injections Work

Prescription appetite suppressant shots available in the UK work primarily through GLP-1 (glucagon-like peptide-1) receptor agonism, a mechanism that mimics natural gut hormones to regulate hunger and satiety signals in the brain [1]. These injectable medications slow gastric emptying, increase feelings of fullness after meals, and reduce food cravings between eating occasions.

Clinical evidence demonstrates that GLP-1 receptor agonists produce significantly greater weight reduction than diet and exercise alone. In the STEP 1 trial, participants using semaglutide achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% in the placebo group [2]. Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed even more pronounced effects with up to 22.5% average weight loss in the SURMOUNT-1 trial [1].

At Cured Pharmacy, we dispense three licensed appetite suppressant injections: Mounjaro (tirzepatide) from £135.00 Wegovy (semaglutide) from £135.00 and Saxenda (liraglutide) from £135.00. Each requires clinical assessment by our UK prescribers to ensure suitability and safety for your individual circumstances.

Mounjaro: The Dual-Action Appetite Suppressant Shot

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, producing complementary metabolic effects that enhance appetite suppression and weight reduction.

In head-to-head comparisons, tirzepatide demonstrated superior efficacy to semaglutide. The SURPASS-2 trial showed participants on the highest tirzepatide dose achieved 5.5 kg greater weight loss than those on semaglutide 1 mg over 40 weeks [3]. This dual mechanism makes Mounjaro particularly effective for patients who need substantial weight reduction under medical supervision.

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen. Dosing typically begins at 2.5 mg weekly and increases gradually every four weeks to minimise gastrointestinal side effects, with maintenance doses ranging from 5 mg to 15 mg depending on individual response and tolerability.

Who Can Use Mounjaro for Appetite Suppression?

Mounjaro is licensed in the UK for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [1]. Our UK prescribers assess your medical history, current medications, and weight management goals during your free consultation to determine whether tirzepatide is appropriate for you.

Wegovy and Saxenda: Established GLP-1 Appetite Suppressants

Wegovy contains semaglutide, a once-weekly GLP-1 receptor agonist that has been extensively studied in the STEP clinical trial programme. Across four major trials involving over 4,500 participants, semaglutide 2.4 mg consistently produced average weight reductions between 12.4% and 17.4% over 68 weeks when combined with lifestyle interventions [2][4].

Saxenda contains liraglutide, a daily GLP-1 injection that was the first in its class licensed specifically for weight management in the UK. While requiring daily administration rather than weekly dosing, Saxenda offers a lower starting price point and may suit patients who prefer more frequent, smaller doses. Clinical trials showed average weight loss of 8% over 56 weeks in the SCALE programme [5].

Both medications work through the same core mechanism—activating GLP-1 receptors to suppress appetite and slow gastric emptying—but differ in dosing frequency, molecular structure, and duration of action. Your UK prescriber will recommend the most appropriate option based on your lifestyle, medical history, and weight management objectives.

Comparing Weekly vs Daily Appetite Suppressant Injections

Weekly injections like Wegovy and Mounjaro offer convenience and consistent therapeutic levels with less frequent administration, whilst daily injections like Saxenda allow for more flexible dose adjustments and may produce fewer initial gastrointestinal effects due to gradual daily dosing. Neither approach is inherently superior—the choice depends on your personal preferences and clinical suitability as determined during your consultation.

What to Expect During Your Appetite Suppressant Shot Treatment

Most patients begin noticing reduced appetite within the first week of treatment, though maximum weight loss effects typically develop over 16-20 weeks as the dose is gradually increased [2]. Common initial side effects include mild nausea, occasional vomiting, diarrhoea, and constipation, which usually diminish within 4-8 weeks as your body adapts to the medication.

Our UK clinical team follows NICE guidance on dose escalation to minimise adverse effects whilst optimising therapeutic benefit. For Wegovy, this involves starting at 0.25 mg weekly and increasing monthly to a maintenance dose of 2.4 mg. Mounjaro follows a similar titration schedule from 2.5 mg to maintenance doses between 5-15 mg. Saxenda increases from 0.6 mg daily to 3 mg over five weeks.

Throughout your treatment, you'll receive ongoing support from our UK-registered pharmacists. We recommend monitoring your weight fortnightly, maintaining a food diary during the first month, and scheduling follow-up consultations every 12 weeks to assess progress and adjust treatment as needed. All patients should combine appetite suppressant injections with a reduced-calorie diet and increased physical activity for optimal results.

Safety Considerations and Contraindications for Appetite Suppressant Shots

GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1][2]. They should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment and for two months after discontinuation.

Our UK prescribers carefully screen for conditions that may affect suitability, including severe gastrointestinal disease, diabetic retinopathy, history of pancreatitis, and renal impairment. Patients taking other medications that slow gastric emptying or affect blood glucose levels require particularly careful assessment to avoid drug interactions.

Serious adverse effects are uncommon but may include pancreatitis, gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications. Superintendent pharmacist Tarun Kumar (GPhC 2233073) and our clinical team provide comprehensive safety information during your consultation and monitor for any concerning symptoms throughout your treatment course.

When to Contact Your Prescriber During Treatment

Seek immediate medical advice if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, visual changes, or signs of allergic reaction. Contact our clinical team on (+44) 116 4646009 if you have concerns about side effects, need dose adjustment advice, or experience any unexpected symptoms during your appetite suppressant injection treatment.

How to Buy Prescription Appetite Suppressant Shot Online UK from Cured Pharmacy

Our streamlined process ensures you can access prescription appetite suppressant injections safely and conveniently. Start by completing our free online consultation, which takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications. Our UK-registered prescribers review every consultation individually—we never use automated approvals.

Once your consultation is approved, we'll dispense your medication from our GPhC-registered pharmacy (registration number 9012511) and arrange discreet delivery to your preferred UK address. All packaging is completely unmarked with no external indication of contents. We offer transparent upfront pricing with no hidden consultation fees—the price you see includes both medication and clinical assessment.

We guarantee the lowest prices in the UK for genuine, licensed appetite suppressant injections. Our prices are clearly displayed before you begin your consultation: Mounjaro from £135.00 Wegovy from £135.00 and Saxenda from £135.00. Every medication is sourced directly from licensed UK wholesalers and comes with full patient information leaflets and injection technique guidance. If you have questions at any stage, our pharmacy team is available by phone during business hours to provide expert support.

Ongoing Prescription Management and Repeat Orders

After your initial prescription, we make repeat orders simple and convenient. Log into your account to request refills, which our prescribers review to ensure continued suitability. We'll send reminders before your medication runs out and can arrange regular deliveries to maintain consistent treatment without interruption. All repeat prescriptions undergo the same clinical oversight as your initial consultation to ensure ongoing safety and efficacy.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & SCALE Obesity and Prediabetes NN8022-1839 Study Group. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.